Metraipolis › archive › dc_d1b7d1fbca2b
RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1 — Europe PMC PMID:41650121
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41650121
- DOI
- 10.1371/journal.pone.0341778
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T02:07:02.860Z
- SHA-256 of the archived text
851ddd1aa88199d340e9cd2bd1357583e0ec9816a649dd5de39cc821699bf6dd- Stable URL of this page
https://metraipolis.com/documento/dc_d1b7d1fbca2b
How to cite
RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1 — Europe PMC PMID:41650121 — Europe PMC (en), https://europepmc.org/article/MED/41650121 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d1b7d1fbca2b (Metraipolis archive dc_d1b7d1fbca2b, sha256 851ddd1aa88199d340e9cd2bd1357583e0ec9816a649dd5de39cc821699bf6dd)
BibTeX
@misc{dcd1b7d1fbca2b,
title = {RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1 — Europe PMC PMID:41650121},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41650121},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d1b7d1fbca2b; sha256 851ddd1aa88199d340e9cd2bd1357583e0ec9816a649dd5de39cc821699bf6dd},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41650121. Agents can read the archived copy with the MCP tool read_document.